Advance your cell and gene therapy program with high-quality human cellular starting materials and integrated analytics – all in one place.
Cell and gene therapies are heralded as the future of precision medicine, but challenges in obtaining reliable, high-quality cellular starting materials and defining appropriate process analytics threaten to slow progress. Together, Discovery and AllCells provides a revolutionary set of scalable, end-to-end cell and gene therapy solutions.
Over three decades of combined experience serving the CGT market with unrivaled speed, scale, and continuity.
An unmatched network of well-characterized, highly-engaged recallable donors from sites across the US and Europe.
Receive human cellular starting material in as little as 24 hours after placing an order – and make decisions faster with data from integrated analytic services.
Our CGT products come with industry-leading viability for optimal consistency and reproducibility. Get RUO and GMP, fresh and cryopreserved, and normal and mobilized leukopaks to support all stages of development.
Access cell isolation, cell culture, and immunophenotypic and functional profiling services adjacent to donor clinics to help define process analytics and inform decision-making. Our scientific experts help optimize projects with an innovative, collaborative, flexible, and client-centric approach.
Next Generation Cell Therapies: Combined Analytics & Cryopreserved Starting Materials Webinars & Videos
Spatial Analysis of Tumor Microenvironment in Immuno-Oncology Blog Post
Advancing Cell Therapy Success in Solid Tumors Blog Post
Learn more about our CGT capabilities by visiting AllCells.com.
